Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 7OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 7Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Imlunestrant × 1 year × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT05307705 2026-04-20

PIKASSO-01

Eli Lilly and Company

Phase 1 Active not recruiting
193 enrolled
Breast

Breast Neoplasms

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Eli Lilly and Company

Phase 3 Active not recruiting
8,000 enrolled
Breast

Breast Neoplasms

NCT04647487 2025-11-12

EMBER-2

Eli Lilly and Company

Phase 1 Completed
87 enrolled 13 charts
Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡